Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $45.3 million.

  • Revolution Medicines' Change in Accured Expenses rose 340.56% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.0 million, marking a year-over-year increase of 3017.09%. This contributed to the annual value of $22.0 million for FY2024, which is 49.88% up from last year.
  • Per Revolution Medicines' latest filing, its Change in Accured Expenses stood at $45.3 million for Q3 2025, which was up 318.61% from $10.8 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Change in Accured Expenses high stood at $45.3 million for Q3 2025, and its period low was -$21.3 million during Q1 2024.
  • In the last 3 years, Revolution Medicines' Change in Accured Expenses had a median value of $10.3 million in 2024 and averaged $8.6 million.
  • As far as peak fluctuations go, Revolution Medicines' Change in Accured Expenses surged by 2,059.69% in 2021, and later tumbled by 1,113.41% in 2024.
  • Over the past 5 years, Revolution Medicines' Change in Accured Expenses (Quarterly) stood at $3.7 million in 2021, then plummeted by 179.24% to -$3.0 million in 2022, then tumbled by 112.10% to -$6.3 million in 2023, then surged by 390.86% to $18.3 million in 2024, then soared by 340.56% to $45.3 million in 2025.
  • Its Change in Accured Expenses stands at $45.3 million for Q3 2025, versus $10.8 million for Q2 2025 and $1.5 million for Q1 2025.